An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease

被引:65
|
作者
Sykes, AP
Brampton, C
Klee, S
Chander, CL
Whelan, C
Parsons, ME
机构
[1] Univ Hertfordshire, Dept Biosci, Hatfield AL10 9AB, Herts, England
[2] Univ Luton, Fac Sci Technol & Design, Dept Biol & Hlth Sci, Luton LU1 3JU, Beds, England
关键词
inflammatory bowel disease; nicotine; TNBS; sulphasalazine; TNF alpha;
D O I
10.1007/s000110050597
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and Design: To determine the effect of nicotine on colonic inflammation in the trinitrobenzenesulphonic acid (TNBS) model of inflammatory bowel disease in comparison with sulphasalazine. Materials: Male Wistar rats were used for the in-vivo and exvivo studies. In-vitro studies were performed using human leukemia peripheral blood monocyte cells (THP-1 cells) grown in continuous culture. Treatment: Rats were given access to either nicotine (5 or 100 mu g/mL) or sulphasalazine (375 mu g/mL) in their drinking water for 10 or 2 days respectively before and 3 days after TNBS administration. THP-1 cells were treated with nicotine (10(-14) to 10(-11) M) for 2h before and after stimulation with 3 mu g/mL lipopolysaccharide (LPS). Methods: Inflammation in the TNBS model was assessed by measuring the tissue myeloperoxidase activity, leukotriene B-4 concentration, inducible nitric oxide protein expression, the ex-vivo production of tumour necrosis factor alpha (TNF alpha), macroscopic damage score, plasma corticosterone levels and by a qualitative histological evolution. The effect of nicotine on TNF alpha production in LPS stimulated THP-1 monocyte cells in-vitro was also determined. Statistical comparisons were made using the Mann-Whitney U-test for the macroscopic damage score and an ANOVA for all other parameters. Results. TNBS treated rats given access to 100 mu g/mL nicotine in their drinking water had a marked reduction in several of the markers of inflammation compared to control TNBS treated rats, but a greater reduction was found at 5 pg/mL, nicotine or 375 mu g/mL sulphasalazine, the latter producing comparable reductions in inflammation to the low dose nicotine. Nicotine also caused a significant reduction in TNF alpha release from THP-1 cells. Conclusions: Nicotine reduced inflammation in the TNBS model of colonic damage confinning the use of nicotine in IBD although the choice of dose requires further investigation. The mechanism of action of nicotine does not involve increased corticosterone levels, but may be a consequence of a reduction in TNF alpha or leukotriene B-4 production.
引用
收藏
页码:311 / 319
页数:9
相关论文
共 50 条
  • [31] Mechanisms of tissue damage in inflammatory bowel disease
    Pallone, F
    Monteleone, G
    CURRENT OPINION IN GASTROENTEROLOGY, 2001, 17 (04) : 307 - 312
  • [32] PATHOGENETIC MECHANISMS OF INFLAMMATORY BOWEL-DISEASE
    CAPRILLI, R
    PENA, AS
    DIANZANI, F
    PALLONE, F
    VERNIA, P
    ITALIAN JOURNAL OF GASTROENTEROLOGY, 1995, 27 (06): : 313 - 326
  • [33] Mechanisms of action of a multi-component herbal preparation in inflammatory bowel disease: anti-inflammatory activity
    Pique-Borras, M-R
    Jaklin, M.
    Rohrl, J.
    Ammendola, A.
    Kunstle, G.
    PLANTA MEDICA, 2022, 88 (15) : 1555 - 1556
  • [34] Unraveling the mechanisms of thrombosis in inflammatory bowel disease
    Koutroubakis, IE
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (05): : 1325 - 1327
  • [35] The Effect of Protein Nutritional Support on Inflammatory Bowel Disease and Its Potential Mechanisms
    Li, Qingye
    Wang, Jing
    NUTRIENTS, 2024, 16 (14)
  • [36] A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease.
    Baldan-Martin, M.
    Azkargorta, M.
    Aransay, A. M.
    Gil-Redondo, R.
    Moreno-Indias, I.
    Iloro, I.
    Soleto, I.
    Orejudo, M.
    Ramirez, C.
    Lucendo, A. J.
    Gutierrez, C. Rodriguez
    Gutierrez, A.
    Arranz, E. Martin
    Bujanda, L.
    Rodriguez-Lago, I.
    Riestra, S.
    Iglesias-Flores, E.
    Bermejo, F.
    Van Domselaar, M.
    Garcia, M. J.
    Salazar, L. Fernandez
    De Prado, A.
    Calvet, X.
    Torrealba, L.
    Rey, I. Baston
    Pallares, H.
    Ber, Y.
    Carnerero, E. L.
    Casanova, M. J.
    Millet, O.
    Elortza, F.
    Mato, J. M.
    Tinahones, F. J.
    Chaparro, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I85 - I87
  • [37] Exploring Chemoprevention in Colorectal Cancer for Patients with Inflammatory Bowel Disease: Mechanisms of Action and Clinical Aspects
    Fousekis, Fotios S.
    Mpakogiannis, Konstantinos
    Filis, Panagiotis
    Skamnelos, Alexandros
    Christodoulou, Dimitrios K.
    Mauri, Davide
    Katsanos, Konstantinos H.
    CANCERS, 2025, 17 (02)
  • [38] Update on the mechanisms of action of anti-TNF-α antibodies and their clinical implications in inflammatory bowel disease
    Eder, Piotr
    Linke, Krzysztof
    Witowski, Janusz
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 772 - 780
  • [39] Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: Therapeutic efficacy and possible mechanisms of action
    Yousef, Mohammad
    Pichyangkura, Rath
    Soodvilai, Sunhapas
    Chatsudthipong, Varanuj
    Muanprasat, Chatchai
    PHARMACOLOGICAL RESEARCH, 2012, 66 (01) : 66 - 79
  • [40] Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer
    Schwartz, Betty
    Hadar, Yitzhak
    ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (02)